Actelion gaining on Tracleer approval

Actelion (SWX:ATLN) was up CHF4.1 to CHF65 on Wednesday. On Tuesday after market close, the FDA had granted marketing approval to ATLN and partner Genentech (DNA) for their Tracleer bosentan oral endo...